Several HESI programs will be featured throughout the meeting.
Environmental Mutagenesis & Genomics Society 54th Annual Meeting
September 9, 2023 – September 13, 2023
Chicago, IL, USA
The mission of this committee is to improve the scientific basis of the interpretation of results from genetic toxicology tests for purposes of more accurate hazard identification and assessment of human risk; to develop follow-up strategies for determining the relevance of test results to human health; to provide a framework for integration of testing results into a risk-based assessment of the effects of chemical exposures on human health; to promote the integration and use of new techniques and scientific knowledge in the evaluation of genetic toxicology; and to monitor and promote the development of innovative tests and testing strategies.
The HESI GTTC Education and Science Outreach Committee is excited to announce the recipients of the 2024 Professional Development Travel Award and the inaugural Training Award.
The Professional Development Travel Award offers individuals with the opportunity to attend scientific conferences or workshops, while the Training Award supports travel for specific training programs (e.g., training courses, cross-lab training) to enhance core competencies and transferable skills. As part of this recognition, the awardees will be invited to GTTC’s 2025 Annual Meeting, where they will have the chance to engage with emerging projects and scientific advancements at HESI and to connect with industry, academic, and government experts in the genetic toxicology field.
Congratulations to all the well-deserving recipients! We wish them continued success in their scientific endeavors.
2023 Spring Awardees: Tony Okeke (Drexel University), Ammer Khawam (McGill University), Natalia Bertolez (University of Coruna), Sarah Park (Oak Ridge, US EPA), Victoria Bastos (Maastricht University), Alper Alcarez (NIEHS), Idoia Meaza Izusi (University of Louisville)
2022 Spring: Jonathan Axellson (UOttawa), Julie Sanders (Sciensano), Anouk Thienpont (VUB), Sam Vielee (U Louisville), David Schuster (UOttawa), Danila Cuomo (Texas A&M).
2022 Fall: Zhenming Yang (Rutgers), Lee Pribyl (MIT), Natalie Laspata (Pittsburg), Daniela Muoio (Pittsburg), Elizabeth Irvin (NC State), Rebekah Petroff (Michigan).
Since its launch in 2022, the Education and Science Outreach Working Group has aimed to promote genetic toxicology as a career path and equip the next generation of scientists with foundational skills and experiences. By creating opportunities for networking, skill-building, and mentorship, the group supports early-career researchers in advancing their expertise and connecting with leaders in the field. In 2024, the program broadened its scope to introduce two new awards that help trainees share their research and grow professionally.
GTTC offers three professional development awards:
All awardees are invited to the GTTC Annual Meeting to learn about emerging projects and science at HESI and to network with experts in the gene toxicology field.
Leadership Team:
Joel Bercu (Gilead), Erica Briggs (Litron Laboratories)
HESI Staff:
Raechel Puglisi, MPH
This working group is focused on evaluating error corrected next generation sequencing (ecNGS) as an alternative method for assessing in vivo mutagenesis. It’s current focus is on investigating the suitability of ecNGS for regulatory mutagenicity testing. In 2023, the group published a position and review paper on this technology and has recently submitted a paper focused on the sensitivity of Duplex Sequencing through a reconstruction experiment. New initiatives include:
Leadership Team:
Shaofei Zhang (Pfizer), Barbara Parsons (US FDA/NCTR)
HESI Staff:
Connie Chen, PhD, MPH
This working group focuses on developing and refining protocols for assessing genotoxic effects on germ cells. The group has published a manuscript on the impact of analyzing mutations in fast-proliferating tissues at different sampling times. Current efforts include drafting a review paper and collecting data to support UN GHS germ cell criteria for the classification and labeling of chemicals. New workstreams being discussed included:
Leadership Team:
Francesco Marchetti, PhD (Health Canada), Jan van Benthem, PhD (RIVM, Retired)
HESI Staff:
Connie Chen, PhD, MPH
This working group is dedicated to establishing consistent methods for compiling, maintaining, and monitoring historical control ranges through consensus among testing laboratories, industry, and regulators. A survey was distributed to gather insights into best practices, with preliminary results presented at IWGT. The group is now discussing additional analyses and planning next steps for data collection.
Leadership Team:
Robert Heflich (US Food and Drug Administration), Robert Smith (Labcorp)
HESI Staff:
Connie Chen, PhD, MPH
This working group aims to critically evaluate new approach methodologies (NAMs) for in vitro genotoxicity testing, aiming to expand current testing strategies and ultimately make recommendations for creating an “in vitro only” approach for genetox testing that meets the needs of various regulatory decision-makers. The group is currently focused on the first of its committee-defined goals, which involves a comprehensive critical evaluation of NAMS through four focus areas:
Leadership Team:
Marc Beal (Health Canada), Giel Hendriks, PhD (Toxys B.V.)
Subteam Leadership: IVIVE – Alexandra Long (Health Canada); Metabolism – Nikolai Chepelev (Health Canada), Xiaoqing Guo (US FDA/NCTR); Indirect GTX – Ashley Allemang (P&G), Inger Brandsma (Toxys); Aneugens – Xiaowen Sun (Pfizer)
HESI Staff:
Alexandra Taraboletti, PhD; Connie Chen, PhD, MPH
This working group is dedicated to offering detailed guidance and best practices for selecting and conducting in vivo tests following a positive genotoxicity result. A key focus is ensuring that follow-up testing aligns with regulatory requirements and scientific best practices. One subgroup is focused on cytotoxicity of in vivo comet assays (data collection for retrospective analysis and development of a novel in vivo study). The recent pilot study data are under analysis, and the workgroup is planning out a new phase of work. This phase will focus on:
Leadership Team:
Carol Beevers (Corteva), Matt LeBaron (Dow Chemical Company), David Lovell (St. George’s University of London)
HESI Staff:
Connie Chen, PhD, MPH
The MRGA working group integrates the efforts of the former MOA and Clean Sheet working groups to establish a new mechanism-based paradigm for genotoxicity risk assessment. The group is composed of two subgroups focusing on Nitrosamines, and Titanium Dioxide (TiO2).
Nitrosamines Subteam
The primary objective of this subteam is to advance the scientific understanding and risk assessment of nitrosamines’ genotoxic potential through innovative mechanism-based testing approaches. (Leadership Team: Tetyana Cheairs (NY Medical College), Andreas Czich (Sanofi))
This subteam has four working groups:
For more information about this subgroup – https://hesiglobal.org/gttc-nitrosamines/
TiO2 Subteam
TiO₂ serves as a data-rich case study, offering a complementary perspective to nitrosamines due its (likely) secondary mode of action and broad stakeholder interest to . This subteam aims to elucidate the mode of action, addressing data gaps, and advancing mechanism-based risk assessment strategies. Key objectives include:
Leadership Team:
Stefan Pfuhler (P&G), Paul Fowler (FS Tox Consulting)
HESI Staff:
Connie Chen, PhD, MPH
This working group is completing several OECD AOP wikis. The first AOP “Oxidative DNA damage leading to mutations and chromosomal damage” was published on the AOPWiki in April 2023. The tubulin binding and topoisomerase II inhibition AOPs will be completed in early 2024, after which this work group will merge into the new MGRA work group.
Leadership for Tubulin binding AOP:
Yasmin Dietz (Sanofi)
Leadership for Topoisomerase II AOP:
Xiaowen Sun (Pfizer), Ryan Wheeldon (J&J)
HESI Staff:
Connie Chen, PhD, MPH
This working group is driving advancements in genetic toxicology by evaluating chemical data and enhancing dose-response modeling tools. Key projects include:
Research highlights involve optimizing in vivo study designs for precise Benchmark Dose (BMD) calculations and assessing inter-individual DNA repair variability. Moving forward, the QA Working Group will focus on developing guidance for the standardized application and regulatory acceptance of the BMD approach in genetic toxicology. These efforts aim to promote broader adoption of dose-response modeling in regulatory decision-making.
Leadership Team:
George Johnson (Swansea University), Andreas Zeller (Roche), Paul White (Health Canada)
HESI Staff:
Alexandra Taraboletti, PhD
Litron Laboratories
Swansea University
September 9, 2023 – September 13, 2023
Chicago, IL, USA
Several HESI programs will be featured throughout the meeting.
May 31, 2023 – June 1, 2023
Webcast, Washington DC
This workshop will engage invited stakeholders and key opinion leaders with expertise in the assessment of nitrosamines (NA), including Nitrosamine Drug Substance-related Impurities (NDSRI) detection and evaluation in order to achieve the following:
May 7, 2023 – May 9, 2023
GTTC, Annual Meeting
Save the Date! The GTTC will hold their Annual Meeting from May 7-9th, 2023.
April 30, 2023
GTTC Professional Development Award, Application due by 30 April 2023
Deadline to apply for the HESI GTTC Professional Development Award is 30 April 2023.
Frontiers in Toxicology, Nanotoxicology, 2022
Abstract: Genotoxicity testing is performed to determine potential hazard of a chemical or agent for direct or indirect DNA interaction. Testing may be a surrogate for assessment of heritable genetic risk or carcinogenic risk. Testing of nanomaterials (NM) for hazard identification is generally understood to require a ...
Environmental and Molecular Mutagenesis, 2014
Genetic toxicology data have traditionally been employed for qualitative, rather than quantitative evaluations of hazard.
Mutation Research/Reviews in Mutation Research, 2023
In this review, we discuss promising applications, challenges, limitations, and key data initiatives needed to enable regulatory testing and adoption of ecNGS.
Nature Reviews Drug Discovery, 2023
The GTTC is pleased to share its newest publication, “Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing,” published in Nature Reviews Drug Discovery. The commentary highlights the potential applications, advantages and challenges associated with ...
Environmental and Molecular Mutagenesis, 2022
The GTTC’s Quantitative Analysis Workgroup recent publication focuses on the quantitative relationships between carcinogenic potency and mutagenic potency.
Environmental and Molecular Mutagenesis, 2011
Appropriate follow-up actions and decisions are needed when evaluating and interpreting clear positive results obtained in the in vitro assays used in the initial genotoxicity screening battery (i.e., the battery of tests generally required by regulatory authorities) to assist in overall risk-based decision making ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.